Insulet Co. (NASDAQ:PODD) Shares Sold by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. cut its position in Insulet Co. (NASDAQ:PODD - Free Report) by 2.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 217,642 shares of the medical instruments supplier's stock after selling 6,400 shares during the quarter. Insulet comprises 0.8% of Polar Asset Management Partners Inc.'s holdings, making the stock its 23rd biggest position. Polar Asset Management Partners Inc. owned approximately 0.31% of Insulet worth $56,820,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Principal Financial Group Inc. grew its stake in shares of Insulet by 4.0% in the third quarter. Principal Financial Group Inc. now owns 86,210 shares of the medical instruments supplier's stock worth $20,065,000 after purchasing an additional 3,355 shares in the last quarter. Czech National Bank grew its position in Insulet by 6.5% in the 4th quarter. Czech National Bank now owns 15,209 shares of the medical instruments supplier's stock valued at $3,971,000 after buying an additional 926 shares in the last quarter. Cooper Financial Group grew its position in Insulet by 14.2% in the 4th quarter. Cooper Financial Group now owns 1,021 shares of the medical instruments supplier's stock valued at $267,000 after buying an additional 127 shares in the last quarter. Board of the Pension Protection Fund acquired a new position in Insulet during the 4th quarter valued at about $418,000. Finally, Assenagon Asset Management S.A. raised its position in shares of Insulet by 8.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 104,392 shares of the medical instruments supplier's stock worth $27,254,000 after buying an additional 8,102 shares in the last quarter.

Insulet Price Performance

PODD opened at $321.41 on Thursday. Insulet Co. has a 12-month low of $170.67 and a 12-month high of $323.00. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The firm has a market capitalization of $22.62 billion, a P/E ratio of 55.51, a PEG ratio of 3.62 and a beta of 1.26. The stock has a fifty day moving average of $260.85 and a 200-day moving average of $265.20.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. The firm had revenue of $569.00 million during the quarter, compared to analyst estimates of $543.20 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business's quarterly revenue was up 28.8% compared to the same quarter last year. During the same period last year, the company posted $0.73 EPS. Equities analysts forecast that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insider Transactions at Insulet

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now directly owns 3,231 shares in the company, valued at $888,525. This trade represents a 36.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.39% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Canaccord Genuity Group increased their price objective on shares of Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a report on Friday, February 21st. Oppenheimer increased their price target on Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Wolfe Research raised Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price objective on the stock in a research note on Tuesday. Stifel Nicolaus upped their price objective on Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a report on Friday, February 21st. Finally, Barclays lifted their target price on Insulet from $234.00 to $266.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 30th. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $306.53.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.